Vantage logo

Hard knocks for brain cancer, again

In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.

Vantage logo

Merck sees potential in Peloton 

Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…

Vantage logo

Myovant punished for success

A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.